We're on a Mission.

Our pharmaceutical partners are working on therapeutics targeting the world’s most intractable diseases, and we’re supporting their efforts from the beginning of drug discovery.

Together with our team of scientists, breakthrough technologies, and in-depth analytic services, we’re revolutionizing the drug discovery process — helping our partners tackle previously incurable diseases and promoting a healthier world.

Experts in the Field, Changing the Game

Join Our Team

Recognizing the limitations posed by the standard methods of epitope mapping, and determined to offer a superior alternative to drug makers, our team of leading scientists and researchers from the University of Wisconsin Madison came together to found Immuto Scientific. Today, we’re putting to use our cutting-edge technologies to accelerate the drug discovery process and help develop new lifesaving therapeutics.

Immuto Executives

Dr. Sussman is the co-founder of Immuto Scientific and one of the inventors of Immuto’s core technology- PLIMB. Dr. Sussman is a Professor in the Dept, of Biochemistry and from 1998-2018, served as Director of the Biotechnology Center at the University of Wisconsin- Madison. He received his PhD from Michigan State University and Postdoc from Yale University.

Faraz A Choudhury, PhD

CEO

Daniel Benjamin, PhD

CTO

Mike Sussman, PhD

CSO

Brad Chandler

CFO

Faraz A Choudhury, PhD

President and CEO
Immuto Scientific Inc.

Faraz A. Choudhury, PhD is the President and CEO of Immuto Scientific. Dr. Choudhury co-founded Immuto Scientific in 2018. As the CEO, he defined the vision and strategy, contributed to core inventions, and is currently responsible for the operations and management of the company. Dr. Choudhury co-invented Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology and he has been involved in the design, development and application of the technology from the inception. His doctorate research work focused on developing plasma technologies for semiconductor manufacturing as well as biological applications. After completing his postdoctoral training, he spent several years as a Research Scientist in the Department of Biochemistry at the University of Wisconsin- Madison (UW Madison). His research focused on proteomics, epitope mapping and protein-protein interactions studies using mass spectrometry. Dr. Choudhury served as a Principal Investigator (PI) on two grants and has been involved as co-investigator or contributor to several other grants from NIH, NSF, NIFA, WARF and WEDC totaling over $1.4M. He administered the projects, developed research plans, collaborated with other researchers, and produced several peer-­reviewed publications and two patents.

Education & Credentials
Post Doctorate:
University of Wisconsin- Madison
Ph.D.,
University of Wisconsin- Madison
B.A.,
Lawrence University

Brad Chandler

CFO

Brad Chandler is a Board Member and Chief Financial Officer of Immuto Scientific. Prior to Immuto, Brad was a Managing Director in the Investment Banking Division of Morgan Stanley in New York City.  Brad is also the Director of the Nicholas Center for Corporate Finance and Investment Banking at the Wisconsin School of Business.  Brad holds a JD from the University of Chicago Law School, an MBA from the University of Chicago Booth School of Business and a BA from Duke University.

Mike Sussman, PhD

CSO

Dr. Sussman is the co-founder of Immuto Scientific and one of the inventors of Immuto's core technology- PLIMB. Dr. Sussman is a Professor in the Dept of Biochemistry and from 1998- 2018, served as Director of the Biotechnology Center at the University of Wisconsin-Madison. He received his PhD from Michigan State University and Postdoc from Yale University.


Daniel Benjamin, PhD

CTO
Immuto Scientific Inc.

Dr. Benjamin is the Chief Technology Officer and co-founder of Immuto Scientific. As the CTO, Dr. Benjamin is responsible for leveraging Immuto’s technological resources and expertise to meet the needs of our customers. As one of the inventors of Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology, Dr. Benjamin spearheaded the design, development, and engineering of the technology. His doctorate research work focused on development the PLIMB technology and proving its application for applications relevant to biopharmaceutical research.

Education & Credentials
Ph.D.,
University of Wisconsin – Madison
M.S.,
University of Wisconsin – Madison
B.A.,
University of Wisconsin – Madison

Immuto Board Members

John D Wiley, PhD

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Brad Chandler

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Matt Kelly

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Greg Keenan

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

St John Skilton, PhD

St John is VP of Marketing and Product Strategy at protein Metrics, Inc. (PMI) which is one of the leading Mass Spec Software solutions providers. He joined Protein Metrics as a startup and has led the sales and marketing efforts since 2015, with growth at triple and double-digit levels from the outset. Until August 2021 he was VP of Sales and Support.

Before joining PMI, he was Senior Manager, Global Markets, Biologics at Sciex (Danaher) providing business insight, sales training, and product development direction for the Pharmaceutical business unit. He had previously been at Waters as a Senior Market Manager for Biopharma, leading a team of technical marketing experts. Prior to that he was in Sales leadership positions, worldwide. His experience in sales, marketing, business development, and analyst roles has helped provide a rounded view of product portfolios and how to deliver tools that are meaningful for customers.

St John studied Chemical Engineering and Chemistry at theUniversity of Cape Town, and has a PhD from the University of Fribourg.

St John Skilton, PhD

St John is VP of Marketing and Product Strategy at protein Metrics, Inc. (PMI) which is one of the leading Mass Spec Software solutions providers. He joined Protein Metrics as a startup and has led the sales and marketing efforts since 2015, with growth at triple and double-digit levels from the outset. Until August 2021 he was VP of Sales and Support.

Before joining PMI, he was Senior Manager, Global Markets, Biologics at Sciex (Danaher) providing business insight, sales training, and product development direction for the Pharmaceutical business unit. He had previously been at Waters as a Senior Market Manager for Biopharma, leading a team of technical marketing experts. Prior to that he was in Sales leadership positions, worldwide. His experience in sales, marketing, business development, and analyst roles has helped provide a rounded view of product portfolios and how to deliver tools that are meaningful for customers.

St John studied Chemical Engineering and Chemistry at the University of Cape Town, and has a PhD from the University of Fribourg.

Greg Keenan

Greg is a Senior Director of Ventures & Accelerator at WARF. He has a M.S.E. Management of Technology from University of Pennsylvania with more than 20 years technology commercialization experience, including leadership positions in Fortune 500, startup and small-cap public companies.

Matt Kelly

Matt is a co-manager at Wisconsin Investment Partners (WIP). Matt brings four years of experience as a major project finance attorney at Milbank, Tweed, Hadley & McCloy, LLP, one of the world’s leading law firms. He graduated cum laude from American University, Washington College of Law, where he served as Senior Note & Comment Editor on the Social Policy law journal. In addition to his law degree, Matt has a B.S. in Biochemistry and History from the University of Wisconsin-Madison.

Brad Chandler

Brad Chandler is a Board Member and Chief Financial Officer of Immuto Scientific. Prior to Immuto, Brad was a Managing Director in the Investment Banking Division of Morgan Stanley in New York City.  Brad is also the Director of the Nicholas Center for Corporate Finance and Investment Banking at the Wisconsin School of Business.  Brad holds a JD from the University of Chicago Law School, an MBA from the University of Chicago Booth School of Business and a BA from Duke University.

John D Wiley, PhD

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Scientific Advisors

Gopalan Raghunathan, PhD

Biologics Discovery, Merck

Richard Burgess, PhD

Emeritus Professor Oncology, University of Wisconsin- Madison

J. Leon Shohet, PhD

Emeritus Professor Electrical Engineering, University of Wisconsin- Madison

Wasfi AlAzzam, PhD

Director, Takeda Pharmaceuticals

Immuto Careers

Scientist
Wisconsin
Full-time
Job spec
Let's Talk

We’re on
a Mission.

Our pharmaceutical partners are working on therapeutics targeting the world’s most intractable diseases, and we’re supporting their efforts from the beginning of drug discovery.

Together with our team of scientists, breakthrough technologies, and in-depth analytic services, we’re revolutionizing the drug discovery process — helping our partners tackle previously incurable diseases and promoting a healthier world.

Experts in the Field, Changing the Game

Recognizing the limitations posed by the standard methods of epitope mapping, and determined to offer a superior alternative to drug makers, our team of leading scientists and researchers from the University of Wisconsin Madison came together to found Immuto Scientific. Today, we’re putting to use our cutting-edge technologies to accelerate the drug discovery process and help develop new lifesaving therapeutics.

Let's Talk

Immuto Executives

Dr. Sussman is the co-founder of Immuto Scientific and one of the inventors of Immuto’s core technology- PLIMB. Dr. Sussman is a Professor in the Dept, of Biochemistry and from 1998-2018, served as Director of the Biotechnology Center at the University of Wisconsin- Madison. He received his PhD from Michigan State University and Postdoc from Yale University.

Faraz A Choudhury, PhD

CEO

Daniel Benjamin, PhD

CTO

Mike Sussman, PhD

CSO

Brad Chandler

CFO

Faraz A Choudhury, PhD

President and CEO
Immuto Scientific Inc.

Faraz A. Choudhury, PhD is the President and CEO of Immuto Scientific. Dr. Choudhury co-founded Immuto Scientific in 2018. As the CEO, he defined the vision and strategy, contributed to core inventions, and is currently responsible for the operations and management of the company. Dr. Choudhury co-invented Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology and he has been involved in the design, development and application of the technology from the inception. His doctorate research work focused on developing plasma technologies for semiconductor manufacturing as well as biological applications. After completing his postdoctoral training, he spent several years as a Research Scientist in the Department of Biochemistry at the University of Wisconsin- Madison (UW Madison). His research focused on proteomics, epitope mapping and protein-protein interactions studies using mass spectrometry. Dr. Choudhury served as a Principal Investigator (PI) on two grants and has been involved as co-investigator or contributor to several other grants from NIH, NSF, NIFA, WARF and WEDC totaling over $1.4M. He administered the projects, developed research plans, collaborated with other researchers, and produced several peer-­reviewed publications and two patents.

Education & Credentials
Post Doctorate:
University of Wisconsin- Madison
Ph.D.,
University of Wisconsin- Madison
B.A.,
Lawrence University

Daniel Benjamin, PhD

CTO
Immuto Scientific Inc.

Dr. Benjamin is the Chief Technology Officer and co-founder of Immuto Scientific. As the CTO, Dr. Benjamin is responsible for leveraging Immuto’s technological resources and expertise to meet the needs of our customers. As one of the inventors of Immuto Scientific’s PLIMB (Plasma Induced Modification to Biomolecules) technology, Dr. Benjamin spearheaded the design, development, and engineering of the technology. His doctorate research work focused on development the PLIMB technology and proving its application for applications relevant to biopharmaceutical research.

Education & Credentials
Ph.D.,
University of Wisconsin – Madison
M.S.,
University of Wisconsin – Madison
B.A.,
University of Wisconsin – Madison

Mike Sussman, PhD

CSO

Dr. Sussman is the co-founder of Immuto Scientific and one of the inventors of Immuto's core technology- PLIMB. Dr. Sussman is a Professor in the Dept of Biochemistry and from 1998- 2018, served as Director of the Biotechnology Center at the University of Wisconsin-Madison. He received his PhD from Michigan State University and Postdoc from Yale University.


Brad Chandler

CFO

Brad Chandler is a Board Member and Chief Financial Officer of Immuto Scientific. Prior to Immuto, Brad was a Managing Director in the Investment Banking Division of Morgan Stanley in New York City.  Brad is also the Director of the Nicholas Center for Corporate Finance and Investment Banking at the Wisconsin School of Business.  Brad holds a JD from the University of Chicago Law School, an MBA from the University of Chicago Booth School of Business and a BA from Duke University.

Immuto Executives

Mike Sussman, PhD

Dr. Sussman is the co-founder of Immuto Scientific and one of the inventors of Immuto’s core technology- PLIMB. Dr. Sussman is a Professor in the Dept, of Biochemistry and from 1998-2018, served as Director of the Biotechnology Center at the University of Wisconsin- Madison. He received his PhD from Michigan State University and Postdoc from Yale University.

Faraz Choudhury, PhD

CEO

Daniel Benjamin, PhD

CTO

Brad Chandler

CFO

Immuto Board Members

John D Wiley, PhD

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Brad Chandler

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Matt Kelly

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Greg Keenan

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

St John Skilton, PhD

St John is VP of Marketing and Product Strategy at protein Metrics, Inc. (PMI) which is one of the leading Mass Spec Software solutions providers. He joined Protein Metrics as a startup and has led the sales and marketing efforts since 2015, with growth at triple and double-digit levels from the outset. Until August 2021 he was VP of Sales and Support.

Before joining PMI, he was Senior Manager, Global Markets, Biologics at Sciex (Danaher) providing business insight, sales training, and product development direction for the Pharmaceutical business unit. He had previously been at Waters as a Senior Market Manager for Biopharma, leading a team of technical marketing experts. Prior to that he was in Sales leadership positions, worldwide. His experience in sales, marketing, business development, and analyst roles has helped provide a rounded view of product portfolios and how to deliver tools that are meaningful for customers.

St John studied Chemical Engineering and Chemistry at theUniversity of Cape Town, and has a PhD from the University of Fribourg.

St John Skilton, PhD

St John is VP of Marketing and Product Strategy at protein Metrics, Inc. (PMI) which is one of the leading Mass Spec Software solutions providers. He joined Protein Metrics as a startup and has led the sales and marketing efforts since 2015, with growth at triple and double-digit levels from the outset. Until August 2021 he was VP of Sales and Support.

Before joining PMI, he was Senior Manager, Global Markets, Biologics at Sciex (Danaher) providing business insight, sales training, and product development direction for the Pharmaceutical business unit. He had previously been at Waters as a Senior Market Manager for Biopharma, leading a team of technical marketing experts. Prior to that he was in Sales leadership positions, worldwide. His experience in sales, marketing, business development, and analyst roles has helped provide a rounded view of product portfolios and how to deliver tools that are meaningful for customers.

St John studied Chemical Engineering and Chemistry at the University of Cape Town, and has a PhD from the University of Fribourg.

Greg Keenan

Greg is a Senior Director of Ventures & Accelerator at WARF. He has a M.S.E. Management of Technology from University of Pennsylvania with more than 20 years technology commercialization experience, including leadership positions in Fortune 500, startup and small-cap public companies.

Matt Kelly

Matt is a co-manager at Wisconsin Investment Partners (WIP). Matt brings four years of experience as a major project finance attorney at Milbank, Tweed, Hadley & McCloy, LLP, one of the world’s leading law firms. He graduated cum laude from American University, Washington College of Law, where he served as Senior Note & Comment Editor on the Social Policy law journal. In addition to his law degree, Matt has a B.S. in Biochemistry and History from the University of Wisconsin-Madison.

Brad Chandler

Brad Chandler is a Board Member and Chief Financial Officer of Immuto Scientific. Prior to Immuto, Brad was a Managing Director in the Investment Banking Division of Morgan Stanley in New York City.  Brad is also the Director of the Nicholas Center for Corporate Finance and Investment Banking at the Wisconsin School of Business.  Brad holds a JD from the University of Chicago Law School, an MBA from the University of Chicago Booth School of Business and a BA from Duke University.

John D Wiley, PhD

John D. Wiley is a former faculty member and chancellor of the University of Wisconsin-Madison from 2001 to 2008. Prior to serving as chancellor, John was UW–Madison’s provost and vice chancellor for academic affairs from 1994 to 2000. In his role as the university’s chief operating officer and deputy chancellor, he worked closely with deans, faculty, academic staff and student committees in the exercise of shared governance and overall management of the institution.

Scientific Advisors

Gopalan Raghunathan, PhD

Biologics Discovery, Merck

Richard Burgess, PhD

Emeritus Professor Oncology, University of Wisconsin- Madison

J. Leon Shohet, PhD

Emeritus Professor Electrical Engineering, University of Wisconsin- Madison

Wasfi AlAzzam, PhD

Director, Takeda Pharmaceuticals

Immuto Careers

Scientist

Wisconsin

Full-time

Job spec

Get In Touch.

Your therapeutics save lives.
We save you time and resources.

Let's Talk

© Copyright 2021 Immuto Scientific. All rights reserved.